Norris Perne & French LLP Galectin Therapeutics Inc Transaction History

Norris Perne & French LLP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Jul 24, 2018	SELL	$3.16 - $9.16 $33,180 - $96,180	-10,500 Closed	0 $0
Q1 2018 Apr 17, 2018	SELL	$3.78 - $5.97 $75,600 - $119,400	-20,000 Reduced 65.57%	10,500 $50,000
Q3 2017 Nov 01, 2017	BUY	$1.67 - $2.3 $50,935 - $70,150	30,500	30,500 $65,000

9.58M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $162M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Norris Perne & French LLP, based on Form 13F filings with the SEC.

Stay updated on Norris Perne & French LLP with notifications on news.